| Condition |
Trial Name |
Sponsor |
| Solid Tumors |
1403-0002: MDM2 Inhibitor BI 907828 and Anti PD-1 Antibody Ezabenlimab in Select Solid Tumors |
Boehringer Ingelheim |
| Solid Tumors |
1719-001: MRTX1719 in MTAP Deleted Advanced Solid Tumors |
Mirati Therapeutics, Inc. |
| Rectal Cancer |
19-288: Neoadjuvant TSR-042 (dostarlimab) for Patients with Rectal Adenocarcinoma |
Memorial Sloan Kettering Cancer Center |
| Breast Cancer |
ASCENT-03: Sacituzumab Govitecan as First Line Treatment for Patients With Triple Negative Breast Cancer |
Gilead Sciences |
| Breast Cancer |
ASCENT-04: Sacituzumab Govitecan in Combination With Pembrolizumab as First Line Treatment for Patients With PD-L1 Expressing Triple Negative Breast Cancer |
Gilead Sciences |
| Breast Cancer |
ASCENT-05: Adjuvant Sacituzumab Govitecan Plus Pembrolizumab for Patients with Triple Negative Breast Cancer |
Gilead Sciences, Inc. |
| Cachexia in Colorectal or Pancreatic Cancer |
AV-380-22-102: Study of GDF-15 Inhibitor AV-380 for the Treatment of Cachexia in Patients with Metastatic Colorectal or Pancreatic Cancer Receiving First Line Chemotherapy |
AVEO Pharmaceuticals, Inc. |
| Solid Tumors |
BI 1403-0001: MDM2 inhibitor BI 907828 in MDM2 Amplified Advanced Solid Tumors |
Boehringer Ingelheim |
| Breast Cancer |
BRI-ROL-001: SV-BR-1-GM Regimen in Combination With Retifanlimab in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Failed Standard Therapy |
BriaCell Therapeutics Corporation |
| Biliary Tract Cancer, Pancreatic Cancer |
Brightline-2: MDM2 Inhibitor BI 907828 in MDM2 amplified, TP53 Wild Type Pancreatic or Biliary Tract Cancer |
Boehringer Ingelheim |
| Solid Tumor or Lymphoma |
CS5001-101: A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas |
CStone Pharmaceuticals |
| Solid Tumors |
DAY101-102: Pan-RAF Inhibitor DAY101 for Patients with Relapsed/Refractory MAPK-Altered Solid Tumors |
Day One Biopharmaceuticals, Inc. |
| Breast Cancer |
DESTINY-Breast09: Trastuzumab deruxtecan for First Line Treatment of Advanced/Metastatic HER2-Positive Breast Cancer |
AstraZeneca |
| Breast Cancer |
ELEVATE: Elacestrant Combinations for the Treatment of ER+ HER2- Metastatic Breast Cancer After CDK4/6 Inhibitor |
Stemline Therapeutics, Inc. |
| Central Nervous System Cancer |
F8294-201b: BRAF Inhibitor FORE8394 in Recurrent/Refractory BRAF V600E Mutant CNS Malignancy |
Fore Biotherapeutics |
| Solid Tumors |
F8394-201a: BRAF Inhibitor FORE8394 for the Treatment of BRAF Fusion Positive Advanced Solid Tumors |
Fore Biotherapeutics |
| Gastric or Gastroesophageal Junction Cancer |
GEMINI-C: First Line Treatment for Patients with an Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma |
AstraZeneca |
| Head and Neck Squamous Cell Carcinoma |
GS-US-548-5916: Magrolimab Combinations in Recurrent or Metastatic HNSCC |
Gilead Sciences, Inc. |
| Non-Small Cell Lung Cancer |
HARMONIC: A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma |
Lantern Pharma Inc. |
| Colon or Rectal Cancer |
KRYSTAL-10: Adagrasib in KRAS G12C Mutated Colorectal Cancer |
Mirati Therapeutics, Inc. |
| Solid Tumors |
KRYSTAL-1: Multiple Cohort Study of Adagrasib Monotherapy or Combinations for Patients With KRAS G12C Mutant Solid Tumors |
Mirati Therapeutics Inc. |
| Colon or Rectal Cancer |
LUT014 Gel for EGFR-Inhibitor Induced Acneiform Rash |
Lutris Pharma Ltd. |
| Non-Hodgkin Lymphoma |
MorningSun: Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies |
Genentech, Inc. |
| Hyperkalemia/Chronic Kidney Disease |
NYH-01: Hyperkalemia/Chronic Kidney Disease |
Relypsa |
| Solid Tumors |
PRECISION 1: Nab-Sirolimus for the Treatment of Patients With TSC1/2 Mutant Advanced or Metastatic Solid Tumor |
Aadi Bioscience, Inc. |
| Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma |
PRT1419-03: PRT1419 in Patients with Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, or Select B-Cell Malignancies |
Prelude Therapeutics |
| ITP, wAIHA, CAD |
RUBY-4: Povetacicept (ALPN-303) for Patients with Autoimmune Cytopenias |
Alpine Immune Sciences, Inc. |
| Breast Cancer |
SERENA-6: AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression |
AstraZeneca |
| Breast Cancer |
SPI-GCF-104: Same Day Administration of Eflapegrastim to Treat Neutropenia in Patients Being Treated With Neo/Adjuvant Docetaxel Plus Cyclophosphamide |
Spectrum Pharmaceuticals, Inc. |
| Multiple Myeloma |
TAK-573-2001: Modakafusp alfa in Combination with Daratumumab for the Treatment of Relapsed/Refractory Multiple Myeloma |
Takeda Development Center Americas, Inc |
| Solid Tumors |
TAPISTRY: Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You Platform Study |
Hoffmann-La Roche |
| Non-Small Cell Lung Cancer |
TROPION-Lung07: Datopotamab Deruxtecan Combinations vs Standard Chemo/Immunotherapy for the First Line Treatment of Non-Squamous Non-Small Cell Lung Cancer |
Daiichi Sankyo, Inc. |
| Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
ZN-c3-005: Phase 2 Study of ZN‑c3 in High-Grade Serous Ovarian Cancer |
K-Group, Beta, Inc. |
| Cancer Diagnosis |
[Registry] MSK-IMPACT/ACCESS Genomic Profiling in Cancer Patients |
Memorial Sloan Kettering Cancer Center |
| Various Indications |
[Sample Collection] Clinical Biospecimen Procurement Protocol to Support Advancements in Medical Diagnoses of Diseases (PROMEDx) |
Precision for Medicine |
| Solid Tumors |
[Sample Collection] Collection and Distribution of Biofluids for Research Purposes |
Bluestar Genomics |
| Solid Tumors |
[Sample Collection] Detecting cancers Earlier Through Elective plasma-based Cancer SEEK Testing (DETECT-ASCEND 2) |
Exact Sciences Thrive LLC |
| Various Indications |
[Sample Collection] Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients (MTG-022) |
MT Group |
| Various Indications |
[Sample Collection] Prospective Collection of Samples for Research (SERATRIALS-05035) |
SERATRIALS, LLC. |
| Solid Tumors |
[Sample Collection] Vallania: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening |
Freenome Holdings Inc. |
| Solid Tumors |
eNRGy: HER2xHER3 Bispecific Antibody MCLA-128 for the Treatment of an Advanced or Metastatic Solid Tumor Malignancy With a Documented NRG1 Fusion |
Merus N.V. |
